Exploring the therapeutic potential of Ayahuasca: acute intake increases mindfulness-related capacities
详细信息 查看全文
- 作者：Joaquim Soler ; Matilde Elices ; Alba Franquesa ; Steven Barker…
- 关键词：Ayahuasca ; Therapeutic potential ; Mindfulness ; Decentering ; Human
- 刊名：Psychopharmacology
- 出版年：2016
- 出版时间：March 2016
- 年：2016
- 卷：233
- 期：5
- 页码：823-829
- 全文大小：387 KB
- 参考文献：Baer RA, Smith GT, Hopkins J et al (2006) Using self-report assessment methods to explore facets of mindfulness. Assessment 13:27–45CrossRef PubMed
Bishop SR, Lau M, Shapiro S et al (2004) Mindfulness: a proposed operational definition. Clin Psychol Sci Pract 11:230–241CrossRef
Bliss S, McCardle M (2013) An exploration of common elements in dialectical behavior therapy, mentalization based treatment and transference focused psychotherapy in the treatment of borderline personality disorder. Clin Soc Work J 42:61–69CrossRef
Bouso JC, González D, Fondevila S et al (2012) Personality, psychopathology, life attitudes and neuropsychological performance among ritual users of Ayahuasca: a longitudinal study. PLoS One 7:e42421PubMedCentral CrossRef PubMed
Bouso JC, Palhano-Fontes F, Rodríguez-Fornells A et al (2015) Long-term use of psychedelic drugs is associated with differences in brain structure and personality in humans. Eur Neuropsychopharmacol 25:483–492CrossRef PubMed
Brown KW, Ryan RM (2003) The benefits of being present: mindfulness and its role in psychological well-being. J Pers Soc Psychol 84:822–848CrossRef PubMed
Buckholtz NS, Boggan WO (1977a) Monoamine oxidase inhibition in brain and liver produced by beta-carbolines: structure-activity relationships and substrate specificity. Biochem Pharmacol 26:1991–1996CrossRef PubMed
Buckholtz NS, Boggan WO (1977b) Inhibition by beta-carbolines of monoamine uptake into a synaptosomal preparation: structure-activity relationships. Life Sci 20:2093–2099CrossRef PubMed
Carmody J, Baer RA, Lykins ELB, Olendzki N (2009) An empirical study of the mechanisms of mindfulness in a mindfulness-based stress reduction program. J Clin Psychol 65:613–626CrossRef PubMed
Cebolla A, Garcia Palacios A, Soler J et al (2012) Psychometric properties of the Spanish validation of the Five Facets of Mindfulness Questionnaire (FFMQ). Eur J Psychiatry 26:118–126.CrossRef
Coffey KA, Hartman M, Fredrickson BL (2010) Deconstructing mindfulness and constructing mental health: understanding mindfulness and its mechanisms of action. Mindfulness 1:235–253CrossRef
Fábregas JM, González D, Fondevila S et al (2010) Assessment of addiction severity among ritual users of ayahuasca. Drug Alcohol Depend 111:257–261CrossRef PubMed
Foa EB, Riggs DS, Massie ED, Yarczower M (1995) The impact of fear activation and anger on the efficacy of exposure treatment for posttraumatic stress disorder. Behav Ther 26:487–499CrossRef
Fontanilla D, Johannessen M, Hajipour AR et al (2009) The hallucinogen N, N-dimethyltryptamine (DMT) is an endogenous sigma-1 receptor regulator. Science 323:934–937PubMedCentral CrossRef PubMed
Fresco DM, Moore MT, van Dulmen MHM et al (2007a) Initial psychometric properties of the experiences questionnaire: validation of a self-report measure of decentering. Behav Ther 38:234–246CrossRef PubMed
Fresco DM, Segal ZV, Buis T, Kennedy S (2007b) Relationship of posttreatment decentering and cognitive reactivity to relapse in major depression. J Consult Clin Psychol 75:447–455CrossRef PubMed
Frood A (2015) Ayahuasca psychedelic tested for depression. Nature. doi:10.1038/nature.2015.17252
Gasser P, Holstein D, Michel Y et al (2014) Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. J Nerv Ment Dis 202:513–520PubMedCentral CrossRef PubMed
Grob CS, Danforth AL, Chopra GS et al (2011) Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry 68:71–78CrossRef PubMed
Grossman P (2008) On measuring mindfulness in psychosomatic and psychological research. J Psychosom Res 64:405–408CrossRef PubMed
Grossman P (2011) Defining mindfulness by how poorly I think I pay attention during everyday awareness and other intractable problems for psychology’s (re)invention of mindfulness: comment on Brown et al. (2011). Psychol Assess 23:1034–1040, discussion 1041–1046CrossRef PubMed
Hayes-skelton SA, Calloway A, Roemer L, Orsillo SM (2014) Decentering as a potential common mechanism across two therapies for generalized anxiety disorder. J Consult Clin Psychol 83:395–404CrossRef PubMed
Holzel BK, Lazar SW, Gard T et al (2011) How does mindfulness meditation work? Proposing mechanisms of action from a conceptual and neural perspective. Perspect Psychol Sci 6:537–559CrossRef PubMed
Kabat-Zinn J (1990) Full catastrophe living: using the wisdom of your body and mind to face stress, pain, and illness. Delacorte, New York
Kraehenmann R, Preller KH, Scheidegger M et al (2014) Psilocybin-induced decrease in amygdala reactivity correlates with enhanced positive mood in healthy volunteers. Biol Psychiatry
Lilja JL, Lundh L-G, Josefsson T, Falkenström F (2012) Observing as an essential facet of mindfulness: a comparison of FFMQ patterns in meditating and non-meditating individuals. Mindfulness 4:203–212CrossRef
McIlhenny EH, Pipkin KE, Standish LJ et al (2009) Direct analysis of psychoactive tryptamine and harmala alkaloids in the Amazonian botanical medicine ayahuasca by liquid chromatography-electrospray ionization-tandem mass spectrometry. J Chromatogr A 1216:8960–8968CrossRef PubMed
McKenna DJ, Towers GN, Abbott F (1984) Monoamine oxidase inhibitors in South American hallucinogenic plants: tryptamine and β-carboline constituents of ayahuasca. J Ethnopharmacol 10:195–223CrossRef PubMed
Osório F de L, Sanches RF, Macedo LR (2015) Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a preliminary report. Rev Bras Psiquiatr São Paulo Braz 37:13–20CrossRef
Pezawas L, Meyer-Lindenberg A, Drabant EM et al (2005) 5-HTTLPR polymorphism impacts human cingulate-amygdala interactions: a genetic susceptibility mechanism for depression. Nat Neurosci 8:828–834CrossRef PubMed
Raichle ME, MacLeod AM, Snyder AZ et al (2001) A default mode of brain function. Proc Natl Acad Sci U S A 98:676–682PubMedCentral CrossRef PubMed
Riba J (2003) Human pharmacology of ayahuasca. Autonomous University of Barcelona
Riba J, Rodríguez-Fornells A, Urbano G et al (2001) Subjective effects and tolerability of the South American psychoactive beverage Ayahuasca in healthy volunteers. Psychopharmacology (Berl) 154:85–95CrossRef
Riba J, Romero S, Grasa E et al (2006) Increased frontal and paralimbic activation following ayahuasca, the pan-Amazonian inebriant. Psychopharmacology (Berl) 186:93–98CrossRef
Riba J, McIlhenny EH, Bouso JC, Barker SA (2015) Metabolism and urinary disposition of N, N-dimethyltryptamine after oral and smoked administration: a comparative study. Drug Test Anal 7:401–406CrossRef PubMed
Rivier L, Lindgren JE (1972) “Ayahuasca”, the South American hallucinogenic drink: an ethnobotanical and chemical investigation. Econ Bot 26:101–129CrossRef
Sanches RF, Osório FL, dos Santos RG et al (2015) Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a SPECT study. J Clin Psychopharmacol in press
Santos RG, Landeira-Fernandez J, Strassman RJ et al (2007) Effects of ayahuasca on psychometric measures of anxiety, panic-like and hopelessness in Santo Daime members. J Ethnopharmacol 112:507–513CrossRef PubMed
Schultes RE (1980) The botany and chemistry of hallucinogens, Rev. and enl. 2d ed. Thomas, Springfield
Segal ZV, Kennedy S, Gemar M et al (2006) Cognitive reactivity to sad mood provocation and the prediction of depressive relapse. Arch Gen Psychiatry 63:749–755CrossRef PubMed
Sessa B, Johnson MW (2015) Can psychedelic compounds play a part in drug dependence therapy? Br J Psychiatry 206:1–3CrossRef PubMed
Shanon B (2002) The antipodes of the mind: charting the phenomenology of the Ayahuasca experience. Oxford University Press, Oxford
Shapiro S, Carlson LE, Astin J, Freedman B (2006) Mechanisms of mindfulness. J Clin Psychol 62:373–386CrossRef PubMed
Sheline YI, Price JL, Yan Z, Mintun MA (2010) Resting-state functional MRI in depression unmasks increased connectivity between networks via the dorsal nexus. Proc Natl Acad Sci U S A 107:11020–11025PubMedCentral CrossRef PubMed
Soler J, Cebolla A, Feliu-Soler A et al (2014a) Relationship between meditative practice and self-reported mindfulness: the MINDSENS composite index. PLoS ONE 9:e86622PubMedCentral CrossRef PubMed
Soler J, Franquesa A, Feliu-Soler A et al (2014b) Assesing decentering: validation, psychometric properities and clinical usefulness of the Experiences Questionnaire in a Spanish sample. Behav Ther 45:863–871CrossRef PubMed
Suzuki O, Katsumata Y, Oya M (1981) Characterization of eight biogenic indoleamines as substrates for type A and type B monoamine oxidase. Biochem Pharmacol 30:1353–1358CrossRef PubMed
Taylor A, Grant J, Breton E et al (2013) Impact of meditation training on the default mode network during a restful state. 4–14
Teasdale JD, Moore R, Hayhurst H et al (2002) Metacognitive awareness and prevention of relapse in depression: empirical evidence. J Consult Clin Psychol 70:275–287CrossRef PubMed
Tejedor R, Feliu-Soler A, Pascual JC et al (2014) Propiedades psicométricas de la versión española de la Philadelphia Mindfulness Scale. Rev Psiquiatr Salud Ment 7:157–165CrossRef PubMed
Thomas G, Lucas P, Capler NR et al (2013) Ayahuasca-assisted therapy for addiction: results from a preliminary observational study in Canada. Curr Drug Abuse Rev 6:30–42CrossRef PubMed
Tupper KW (2008) The globalization of ayahuasca: harm reduction or benefit maximization? Int J Drug Policy 19:297–303CrossRef PubMed
Veehof MM, Peter M, Taal E et al (2011) Psychometric properties of the Dutch Five Facet Mindfulness Questionnaire (FFMQ) in patients with fibromyalgia. Clin Rheumatol 30:1045–1054PubMedCentral CrossRef PubMed
Vollenweider FX, Kometer M (2010) The neurobiology of psychedelic drugs: implications for the treatment of mood disorders. Nat Rev Neurosci 11:642–651CrossRef PubMed - 作者单位：Joaquim Soler (1) (2) (3)
Matilde Elices (1) (3) (4) (5)
Alba Franquesa (4) (6)
Steven Barker (7)
Pablo Friedlander (8)
Amanda Feilding (8)
Juan C. Pascual (1) (3) (4)
Jordi Riba (10) (11) (3) (9)
1. Servei de Psiquiatria, Hospital de la Santa Creu i Sant Pau (Barcelona), Universitat Autònoma de Barcelona (UAB), Barcelona, Spain
2. Departamento de Psicologia Clínica i de la Salut, Universitat Autònoma de Barcelona, Barcelona, Spain
3. Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, Madrid, Spain
4. Departamento de Psiquiatria i Medicina Legal, Universitat Autònoma de Barcelona, Barcelona, Spain
5. Programa de Cognición, Instituto de Fundamentos y Métodos, Facultad de Psicología, Universidad de la República, Montevideo, Uruguay
6. Les Corts Centre d’Higiene Mental, Barcelona, Spain
7. Department of Comparative Biomedical Sciences, School of Veterinary Medicine, Louisiana State University, Skip Bertman Drive at River Road, Baton Rouge, LA, 70803, USA
8. The Beckley Foundation, Beckley Park, Oxford, OX3 9SY, UK
10. Department of Pharmacology and Therapeutics, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain
11. Human Neuropsychopharmacology Group, Sant Pau Institute of Biomedical Research (IIB-Sant Pau), C/ Sant Antoni María Claret, 167, 08025, Barcelona, Spain
9. Centre d’Investigació de Medicaments, Servei de Farmacologia Clínica, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain - 刊物类别：Biomedical and Life Sciences
- 刊物主题：Biomedicine
Pharmacology and Toxicology
Psychiatry - 出版者：Springer Berlin / Heidelberg
- ISSN：1432-2072
文摘
Background Ayahuasca is a psychotropic plant tea used for ritual purposes by the indigenous populations of the Amazon. In the last two decades, its use has expanded worldwide. The tea contains the psychedelic 5-HT2A receptor agonist N,N-dimethyltryptamine (DMT), plus β-carboline alkaloids with monoamine-oxidase-inhibiting properties. Acute administration induces an introspective dream-like experience characterized by visions and autobiographic and emotional memories. Studies of long-term users have suggested its therapeutic potential, reporting that its use has helped individuals abandon the consumption of addictive drugs. Furthermore, recent open-label studies in patients with treatment-resistant depression found that a single ayahuasca dose induced a rapid antidepressant effect that was maintained weeks after administration. Here, we conducted an exploratory study of the psychological mechanisms that could underlie the beneficial effects of ayahuasca.